GuruFocus.com1d agobearish
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger TalksInvestors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
514last 24h
2492last 7d
477● bullish (7d)
256● bearish (7d)
197publishers
Moby1d agoneutral
AstraZeneca Eyes a Pharma Megamerger Nobody Asked ForThe UK drugmaker is reportedly talking to Bristol Myers Squibb about a nearly $400 billion tie-up, but investors are struggling to diagnose the logic.
24/7 Wall St.1d agoneutral
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
Bloomberg1d agoneutralVIDEO
AstraZeneca Investors See Little Logic in Bristol Tie-UpAstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss.
PA Media: Money2d agoneutral
Stocks mixed as AstraZeneca merger talk dents FTSE 100The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
Pharmaceutical Technology2d agobearish
AstraZeneca shares slump after $400bn BMS merger rumoursOne of the largest global pharma companies would be created if a deal were to materialise.
Investing.com2d agoneutral
Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?BMY surged roughly 6% in premarket trading on the news before fading; the stock is now trading near flat. The asymmetric price reaction captures the market's immediate verdict: AZN shareholders see a value-destructive deal, while BMY holders see a potential premium exit.
MT Newswires2d agoneutral
European Stocks Close Mostly Higher in Monday Trading; AstraZeneca Reportedly in Merger Talks With Bristol MyersEuropean stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa
Zacks2d agoneutral
4 Biotech Stocks Likely to Outpace Q2 Earnings EstimatesMedical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Investopedia2d agobullish
Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZenecaBristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
Investor's Business Daily2d agoneutral
AstraZeneca Stock Nosedives On Mega-Merger RumorAstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.
Proactive2d agoneutral
Medicus Pharma CMO to lead Antev's Teverelix clinical programmeMedicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev’s chief...
Quartz2d agoneutral
AstraZeneca, Bristol Myers Squibb exploring merger talksA combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times
GuruFocus.com2d agoneutral
AstraZeneca Weighs a Deal Its CEO Said It Didn't NeedCombined group would rank fourth by market value
Investopedia2d agoneutral
5 Things to Know Before the Stock Market Opens on MondayNews of the day for Monday, August 3
TheStreet2d agoneutral
Morgan Stanley uncovers major Bristol Myers stock signalsBristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...
Proactive2d agoneutral
Analysts baffled by AstraZeneca's interest in Bristol Myers SquibbAstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 6% to 11,872p on Monday, the steepest decline in the FTSE 100, as analysts struggled to explain why Britain's largest drugmaker would want to buy Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP). Jefferies described the reported talks...
The Wall Street Journal2d agoneutral
Health Care Roundup: Market TalkFind insight on AstraZeneca , Bristol Myers Squibb, Hartalega and more in the latest Market Talks covering health care.
Reuters2d agoneutral
Wall St futures edge up on Mideast deal hopes; healthcare in focusAug 3 (Reuters) - U.S. stock index futures edged higher on Monday as signs of de-escalating tensions in the Middle East weighed on crude prices, while investors prepared for another week packed with
Barrons.com2d agobearish
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZenecaThe merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.
Pharmaceutical Technology2d agoneutral
Ratio Therapeutics secures $70m Series C funding for cancer radiotherapyThe funding will advance its ATLAS trial, assessing lead candidate [Ac-225]RTX-2358, a FAP-targeted radiotherapeutic for advanced sarcomas.
The Wall Street Journal2d agoneutral
Stocks to Watch: Bristol Myers Squibb, Alibaba, Palantir↗️↘️AstraZeneca (AZN, UK:AZN), Bristol Myers Squibb (BMY): The drug companies are in talks to combine in a deal that would value the joint company at roughly $400 billion, the Financial Times reported.
The Wall Street Journal2d agobearish
U.S. Stock Futures Rise, Oil Falls as U.S. Shifts Toward Diplomacy with IranU.S. stocks were on track to extend Friday’s rally as President Trump said he had canceled planned strikes on Iran, adding that peace talks would resume Monday afternoon.